Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow BIOXYTRAN, INC

Get SEC filing alerts via email and in your feed for BIOXYTRAN, INC

BIXT

BIOXYTRAN, INC

About BIOXYTRAN, INC

Bioxytran, Inc. is a clinical-stage pharmaceutical company developing therapeutic drugs targeting hypoxia, a condition of oxygen deficiency in tissues. Its lead candidate, BXT-25, is a novel oxygen-carrying small molecule designed to treat stroke-related brain hypoxia. Through its subsidiary Pharmalectin, the company develops galectin antagonist-based therapies for viral diseases, including COVID-19. Bioxytran focuses on innovative co-polymer chemistry, leveraging proprietary technology to address unmet medical needs via licensing partnerships.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from BIOXYTRAN, INC

1
1
BIOXYTRAN, INC Bioxytran Reports $2.07 Million Net Loss in Q1 2026, Faces Funding Challenges

Via official filing (AI summary) | 19 days ago | 0 comments

2
1
BIOXYTRAN, INC Bioxytran Reports $2.1 Million Net Loss for Fiscal Year 2025, Focuses on R&D and Clinical Trials

Via official filing (AI summary) | about 2 months ago | 0 comments

3
1
BIOXYTRAN, INC Bioxytran Reports Q3 2025 Financial Results with Decreased Losses and Increased Liabilities

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
BIOXYTRAN, INC Bioxytran Reports Q2 2025 Net Profit of $35,437 Amid Ongoing Financial Challenges

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
BIOXYTRAN, INC Bioxytran Reports $1.35 Million Net Loss in Q1 2025 Amid Increased R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
BIOXYTRAN, INC Bioxytran Reports Improved Financials, Reduced Expenses, and Acquisition of NDPD Pharma

Via official filing (AI summary) | over 1 year ago | 0 comments